FINPROVE – Precision Cancer Medicine Stage 3 Signal Confirmation The project is focused on improving cancer treatment by working with European partners like PRIME-ROSE and DRUP-like clinical trials (DLCTs). The collaboration addresses local needs, especially funding and regulations. The trials have shown early signs that some patients benefit from the treatments. If at least five patients show improvement after 16 weeks in the first two stages, we move to a larger stage 3 trial confirmation. DLCTs show that it's possible to use precision cancer treatments locally, with many patients benefiting from targeted therapies. This approach meets local funding requirements and supports international cooperation, helping to expand the use of new treatments. FINPROVE works with other European trials to share data, but stage 3 needs to be handled separately. Funding will support the preparation and running of stage 3 trials, including data management for the PRIME-ROSE collaboration.

2026

2029